Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Among patients with hepatocellular carcinoma whose disease had progressed during receipt of sorafenib or other systemic therapy, median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo. High-grade adverse events were as previously noted for the drug.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-07, Vol.379 (1), p.54-63
Hauptverfasser:	Abou-Alfa, Ghassan K, Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B, Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Chen, YenHsun, Park, Joong-Won, Blanc, Jean-Frederic, Bolondi, Luigi, Klümpen, Heinz-Josef, Chan, Stephen L, Zagonel, Vittorina, Pressiani, Tiziana, Ryu, Min-Hee, Venook, Alan P, Hessel, Colin, Borgman-Hagey, Anne E, Schwab, Gisela, Kelley, Robin K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anilides - adverse effects Anilides - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Aspartate aminotransferase Axl protein Cancer Cancer therapies Carcinoma, Hepatocellular - drug therapy Collaboration Diarrhea Disease-Free Survival Double-Blind Method Double-blind studies Fatigue Female Growth factor receptors Hepatitis Hepatocellular carcinoma Hospitals Humans Inhibitor drugs Kaplan-Meier Estimate Life Sciences Liver cancer Liver Neoplasms - drug therapy Male Medical prognosis Middle Aged Oncology Patients Pyridines - adverse effects Pyridines - therapeutic use Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Survival Targeted cancer therapy Tumors Tyrosine Vascular endothelial growth factor Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among patients with hepatocellular carcinoma whose disease had progressed during receipt of sorafenib or other systemic therapy, median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo. High-grade adverse events were as previously noted for the drug.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1717002